In this randomized , controlled , phase @ study , we assigned @ patients with advanced melanoma in a @:@:@ ratio to receive pembrolizumab ( at a dose of @ mg per kilogram of body weight ) every @ weeks or every @ weeks or four doses of ipilimumab ( at @ mg per kilogram ) every @ weeks .